Cambridge Investment Research Advisors
HQL

Cambridge Investment Research Advisors’s abrdn Life Sciences Investors HQL Stock Holding History

Cambridge Investment Research Advisors’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$226K Buy
13,883
+1,165
+9% +$19.5K ﹤0.01% 3567
2025
Q4 		$213K Buy
12,718
+58
+0.5% +$975 ﹤0.01% 3520
2025
Q3 		$196K Buy
12,660
+1,818
+17% +$24.9K ﹤0.01% 3488
2025
Q2 		$139K Buy
10,842
+320
+3% +$3.94K ﹤0.01% 3429
2025
Q1 		$134K Buy
+10,522
New +$142K ﹤0.01% 3301
2024
Q2 		– Sell
-10,927
Closed -$149K – 3375
2024
Q1 		$149K Buy
10,927
+501
+5% +$6.93K ﹤0.01% 3094
2023
Q4 		$140K Sell
10,426
-1,066
-9% -$13.1K ﹤0.01% 2987
2023
Q3 		$143K Sell
11,492
-765
-6% -$10.1K ﹤0.01% 2900
2023
Q2 		$166K Buy
12,257
+210
+2% +$2.9K ﹤0.01% 2924
2023
Q1 		$168K Buy
+12,047
New +$172K ﹤0.01% 2875
2022
Q3 		– Sell
-15,278
Closed -$217K – 3109
2022
Q2 		$217K Buy
15,278
+348
+2% +$5.26K ﹤0.01% 2668
2022
Q1 		$247K Buy
14,930
+1,982
+15% +$34.1K ﹤0.01% 2704
2021
Q4 		$249K Buy
12,948
+736
+6% +$14.8K ﹤0.01% 2697
2021
Q3 		$254K Buy
12,212
+404
+3% +$8.65K ﹤0.01% 2606
2021
Q2 		$253K Buy
+11,808
New +$238K ﹤0.01% 2600
2019
Q4 		– Sell
-49,523
Closed -$748K – 2439
2019
Q3 		$748K Sell
49,523
-2,603
-5% -$41.7K 0.01% 1248
2019
Q2 		$878K Buy
52,126
+2,863
+6% +$47.2K 0.01% 1094
2019
Q1 		$844K Buy
49,263
+5,308
+12% +$91.6K 0.01% 1127
2018
Q4 		$664K Sell
43,955
-8,876
-17% -$156K 0.01% 1164
2018
Q3 		$1.08M Buy
52,831
+1,264
+2% +$25.1K 0.01% 982
2018
Q2 		$969K Sell
51,567
-649
-1% -$12.2K 0.01% 999
2018
Q1 		$1M Buy
52,216
+962
+2% +$19.3K 0.01% 937
2017
Q4 		$1.01M Buy
51,254
+8,289
+19% +$166K 0.01% 906
2017
Q3 		$923K Buy
42,965
+1,605
+4% +$34.1K 0.01% 882
2017
Q2 		$862K Sell
41,360
-5,233
-11% -$106K 0.01% 879
2017
Q1 		$903K Buy
46,593
+86
+0.2% +$1.59K 0.02% 771
2016
Q4 		$790K Buy
46,507
+1,627
+4% +$28.6K 0.01% 794
2016
Q3 		$841K Sell
44,880
-951
-2% -$17.9K 0.02% 766
2016
Q2 		$788K Buy
45,831
+8,368
+22% +$154K 0.02% 727
2016
Q1 		$672K Buy
37,463
+6,032
+19% +$109K 0.02% 748
2015
Q4 		$743K Buy
31,431
+1,619
+5% +$40.2K 0.02% 670
2015
Q3 		$671K Buy
+29,812
New +$835K 0.02% 630
2014
Q4 		– Sell
-9,303
Closed -$206K – 1430
2014
Q3 		$206K Buy
+9,303
New +$202K 0.01% 1288

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Cambridge Investment Research Advisors's HQL Position: Q1 2026 in Review

Cambridge Investment Research Advisors increased its abrdn Life Sciences Investors (HQL) stake by 9.2% in Q1 2026, buying an estimated $19.5K and bringing the position to 13,883 shares worth $226K. The position accounts for ﹤0.01% of the portfolio, ranked #3567.

Cambridge Investment Research Advisors first reported a position in HQL in Q3 2014 and has held it in 33 quarters since. The position peaked at $1.08M in Q3 2018. 86 funds tracked by Wall St. Rank hold HQL as of Q1 2026.

  • Cambridge Investment Research Advisors held 13,883 shares of abrdn Life Sciences Investors worth $226K as of Q1 2026.
  • Cambridge Investment Research Advisors bought 1,165 abrdn Life Sciences Investors shares in Q1 2026, an estimated $19.5K.
  • abrdn Life Sciences Investors made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q1 2026, its #3567 holding.
  • Cambridge Investment Research Advisors first reported a position in abrdn Life Sciences Investors in Q3 2014 and has held it in 33 quarters since.
  • Cambridge Investment Research Advisors's abrdn Life Sciences Investors position peaked at $1.08M in Q3 2018.
  • 86 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.